Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Int J Neurosci ; 130(11): 1118-1124, 2020 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-32075467

RESUMO

Objective: The objective of the present study was to evaluate the effect of low-dose of ketamine, in short-term, on behavioral impairment and acute neuronal death in the cerebral cortex during the acute phase in a model of epileptic mouse induced by pilocarpine.Methods:Ketamine was administrated (10 mg/kg) intraperitoneally, 30 min before pilocarpine injection (100 mg/kg) in the first group. The second group received the same dose of ketamine 30 min after pilocarpine injection. The effect of ketamine on behavioral disorders and cerebral neuronal integrity in epileptic mice was evaluated.Results:Clinical observations and behavioural tests relate a reduction in behavioural dysfunctions in mice treated with ketamine. Interestingly, treatment of mice with low dose of ketamine decreased the clinical symptoms (movements of the vibrios, nods of the head, and movements of the whiskers), especially when administered before epilepsy induction. Furthermore, the administration of ketamine limits oedema in the hippocampus, neuronal degeneration and gliosis in the different cortical layers. These results could be explained by NMDA receptors inhibition by ketamine.Conclusion:Therefore, it appears that ketamine is endowed with a potential neuroprotective effect and can reduce the severity of neurodegeneration, especially when administrated before Status Epilepticus (SE) installation.


Assuntos
Comportamento Animal/efeitos dos fármacos , Edema Encefálico/prevenção & controle , Córtex Cerebral/efeitos dos fármacos , Epilepsia/tratamento farmacológico , Epilepsia/patologia , Gliose/prevenção & controle , Ketamina/farmacologia , Degeneração Neural/prevenção & controle , Fármacos Neuroprotetores/farmacologia , Receptores de N-Metil-D-Aspartato/antagonistas & inibidores , Animais , Modelos Animais de Doenças , Epilepsia/induzido quimicamente , Hipocampo/efeitos dos fármacos , Injeções Intraperitoneais , Ketamina/administração & dosagem , Camundongos , Fármacos Neuroprotetores/administração & dosagem , Pilocarpina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA